

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Keymed Biosciences Inc.
康諾亞生物醫藥科技有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2162)

INSIDE INFORMATION ANNOUNCEMENT
(1) UPDATE ON PRODUCT REVENUE FOR
THE FIRST THREE QUARTERS OF 2026
AND
(2) NATIONAL MEDICAL PRODUCTS
ADMINISTRATION APPROVES THE NEW
INDICATION MARKETING APPLICATION
FOR STAPOKIBART FOR THE TREATMENT
OF MODERATE-TO-SEVERE ATOPIC
DERMATITIS IN ADOLESCENTS

This announcement is made by Keymed Biosciences Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) is pleased to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that:

(1) UPDATE ON PRODUCT REVENUE FOR THE FIRST THREE QUARTERS OF 2026

It recorded a revenue generated from the Company’s product Kangyueda® (康悦達®) (IL-4Rα monoclonal antibody, Stapokibart) of approximately RMB660 million during the first three quarters of 2026, representing a year-on-year increase of approximately 227%. The core drivers are genuine market demand and the sharp increase in the number of hospitals with market access. Benefiting from the support of national policies, since January 1, 2026, all three approved indications of Kangyueda®, namely moderate-to-severe Atopic Dermatitis (AD) in adults, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) and Seasonal Allergic Rhinitis (SAR), as well as its two packaging formats of vial and pre-filled autoinjector, have been included in China’s National Reimbursement Drug List, with a medical insurance payment standard of RMB1,039 per unit for the 300 mg/2 mL specification, significantly enhancing the affordability of the product for patients in China. Meanwhile, in July 2026, Kangyueda® (康悦達®) was officially included in the National Essential Medicines List (2026 Edition), which took effect on September 1, 2026. Pursuant to the relevant administrative requirements for essential medicines, public medical institutions at all levels nationwide are required to procure and give priority to the use of medicines included in the list. This further broadens terminal prescription settings and enhances the accessibility of medicines.

As of September 30, 2026, the commercialization team had grown to more than 550 members, with market access initiatives progressing rapidly. It covers 30 provinces and nearly 290 cities, including more than 2,200 hospitals. There are approximately 2,200 hospitals with consistent prescription output and more than 1,300 hospitals for in-hospital drug administration. Furthermore, it has stable partnerships with nearly 60 primary distributors, with presence in nearly 700 pharmacies.

(2) NATIONAL MEDICAL PRODUCTS ADMINISTRATION APPROVES THE NEW INDICATION MARKETING APPLICATION FOR STAPOKIBART FOR THE TREATMENT OF MODERATE-TO-SEVERE ATOPIC DERMATITIS IN ADOLESCENTS

The National Medical Products Administration of China (the “NMPA”) has recently approved the marketing application for a new indication of stapokibart (an anti-IL-4R α monoclonal antibody; trade name: Kangyueda (康悦達); development code: CM310) for the treatment of moderate-to-severe atopic dermatitis (AD) in adolescents. Both the vials (300 mg [2 ml]/vial) and the pre-filled auto-injector pens (300 mg [2 ml]/pen) have been approved.

This marketing approval of Stapokibart was based on a randomised, double-blind, placebo-controlled Phase III clinical study evaluating the efficacy and safety in 180 adolescent patients aged 12 or older but younger than aged 18. The study results indicated that, at Week 18 of treatment, up to 73.9% of patients achieved an EASI-75 response, significantly higher than the placebo group (43.3%, $P < 0.0001$). Up to 57.1% of patients achieved IGA response, significantly superior to the placebo group (25.0%, $P < 0.0001$). In addition, the PP-NRS of patients in the Stapokibart group improved by up to 49.5% from baseline. In terms of safety, the incidence rates of treatment-emergent adverse events (TEAEs) in the Stapokibart group and the placebo group were comparable, and most were mild to moderate in severity. Furthermore, compared with the results of studies in adults, the safety profile in adolescent patients with moderate-to-severe AD was favourable, with no new safety signals identified.

About Stapokibart

Stapokibart is a humanized and highly potent antibody against interleukin-4 receptor α -subunit (IL-4R α). It is the first domestically-developed IL-4R α antibody that received marketing application approval from the NMPA and is also the world’s first IL-4R α antibody approved for the treatment of Seasonal allergic rhinitis (SAR) indications. By targeting IL-4R α , Kangyueda (康悦達®) can lead to dual-blockade of interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling. IL-4 and IL-13 are two critical cytokines for initiating type 2 inflammation. In March 2026, the marketing application for Stapokibart injection for prurigo nodularis (PN) was also accepted by the NMPA. As of the date of this announcement, the Company are advancing a randomized, double-blinded, placebo-controlled Phase III clinical study to evaluate the efficacy and safety of Stapokibart in child subjects with moderate-to-severe AD, and patient enrollment is in progress. Meanwhile, in July 2026, the Company initiated a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study evaluating the efficacy and safety of Stapokibart injection under background therapy for the treatment of adolescent patients with SAR.

The financial information contained in this announcement has been prepared based on the internal management records of the Group and has not been audited or reviewed by the external auditor. Accordingly, such information is provided for investors' reference only. Due to various uncertainties arising in the process of collecting and compiling such information, it may differ from the information to be disclosed in the audited or unaudited consolidated financial statements to be published by the Company, including but not limited to information contained in annual or interim disclosures.

There is no assurance that the Company will ultimately market and/or commercialize Stapokibart for other indications under development. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Keymed Biosciences Inc.
Dr. Bo CHEN
Chairman

Hong Kong, October 16, 2026

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Bo CHEN, Dr. Changyu WANG and Dr. Gang XU as executive Directors; Mr. Qi CHEN and Mr. Yilun LIU as non-executive Directors; and Prof. Xiao-Fan WANG, Prof. Yang KE and Mr. Cheuk Kin Stephen LAW as independent non-executive Directors.